DEVELOPMENT OF TYPE II INHIBITORS FOR JNK3

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 JNK3的抑制已被证明可以保护小鼠免受帕金森病小鼠模型中相关的多巴胺能神经细胞丢失的影响。到目前为止，I型ATP竞争性抑制剂已经被设计并成功结晶。然而，晶体结构是处理非活性蛋白质的，而对结合到蛋白质活性形式上的抑制物的翻译尚不清楚。MAP激酶家族中II型抑制剂的发现为我们计划研究的JNK3酶的非活性形式开辟了一条新的靶点。我们认为，这条途径将允许增加激酶和可能的JNK异构体特异性，而更传统的I型抑制剂缺乏。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The inhibition of JNK3 has been shown to protect mice from the dopaminergic neuronal cell loss associated in the mouse model of Parkinson's disease. To date, Type I ATP competitive inhibitors have been designed and successfully crystallized. However, the crystal structures are dealing with inactive protein and the exact understanding of the translation of the inhibitor binding onto the active form of the protein is unknown. The discovery of Type II inhibitors in the MAP kinase family opened up a novel way to specifically target the inactive form of the enzyme which we plan on examining with respect to JNK3. We feel that this path will allow for the increase in kinase and possibly JNK isoform specificity lacking in a more traditional Type I inhibitor.